Navigation Links
VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
Date:12/29/2009

of VIA-2291 on expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiometabolic clinical trials using surrogate endpoints in Phase 1 and Phase 2 clinical trials which may differ from the ultimate endpoints required for registration of a candidate drug;

-- the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;

-- if the results of the ACS and CEA studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials;

-- our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291;

-- our ability to successfully commercialize VIA-2291;

-- our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development;

-- our ability to obtain and protect our intellectual property related to our product candidates;

-- our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche;

-- our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291;

-- our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item 1A "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as supplemented by the risks described under Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009, and September 30, 2009, each on file with the SEC.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Trovagene, Inc. (NASDAQ:  TROV), a developer of ... for the three months ended March 31, 2015. ... presented favorable clinical results at ASCO GI, AACR, ... Precision Cancer Monitoring platform,s ability to detect and ... cancers," said Antonius Schuh, Ph.D., chief executive officer ...
(Date:5/5/2015)... NEW YORK , May 5, 2015  IBM ... it is collaborating with more than a dozen leading ... identify and personalize treatment options for their patients. The ... cognitive capabilities to reduce from weeks to minutes the ... profile and gather relevant information from medical literature to ...
(Date:5/5/2015)... , May 5, 2015 ... at $94.9 million in 2014, and is estimated to ... of 7.8% from 2014 to 2019. Browse ... Device Market for an analysis of industry trends and ... http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html Early ...
Breaking Medicine Technology:Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3
... NEW YORK, Sept. 6, 2011 ... market research report is available ... Licensing Strategies of Large ... Pipelines and the Patent Cliff ...
... Global regenerative medicine company, Mesoblast Limited, (ASX: ... from the European Medicines Agency (EMA) to begin ... Europe for its lead cardiovascular product Revascor(TM) in ... heart failure after a major heart attack. Revascor(TM) ...
Cached Medicine Technology:Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 2Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 3Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 4Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 5Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 6Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 7Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 8Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 9Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 10Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 11Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 12Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 13Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 14Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 15Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity 16Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 2Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 3Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks 4
(Date:5/5/2015)... 2015 ProTexting, LLC – a ... deploy Mobile Engagement Campaigns and other Mobile solutions, introduces ... can now leverage the power of Mobile Marketing to ... subscribers’ e-mail addresses into the Constant Contact Platform. , ... the growing trend of multi-channel marketing would become more ...
(Date:5/5/2015)... DC (PRWEB) May 05, 2015 ... Hope Initiative, a new study aimed at determining how ... patients. RG is an international non-profit providing rare disease ... sequencing technology, connections to scientists and researchers, and help ... crowdfunding. , “I am excited to see how crowdfunding ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 On April ... Los Angeles, CA, Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” ... LA’s leading producer of sustainable product placement in TV ... the world’s top providers of ecologically sound and socially ... premier red carpet event that makes appearances at various ...
(Date:5/5/2015)... Brookfield, Wis. (PRWEB) May 05, 2015 ... security solutions created the Sensatec® ST750 Fall Management Solution ... recording advising the monitored patient or resident to wait ... up. Caregivers also have the choice of 16 different ... into a nurse call system such as Code Alert®. ...
(Date:5/5/2015)... In the upbeat Moms Helping Moms video, real ... support each other. Parenting is a tough job, but ... so much easier. Mothers talk about how relating and ... and help them realize there’s no perfect parent; everyone is ... clearly dear friends share that it's just that, the friendship ...
Breaking Medicine News(10 mins):Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2
... ... within football’s international arena, it is with great pleasure that international direct selling identity, ... of Asian football. , ... (PRWEB) February 19, 2010 -- As the Official Direct Selling Supporter of the ...
... magnetic resonance imaging (MRI) may help physicians differentiate between ... wrist enabling more targeted therapies unique to each condition, ... the American Journal of Roentgenology . Contrast-enhanced MRI ... bodily structures. Rheumatoid arthritis ...
... ... ... ... ...
... ... , ... , , , , ... ...
... ... ... ... ...
... Francisco has signed a partnership agreement with Genentech, Inc., ... discover and develop drug candidates for neurodegenerative diseases. ... research acumen in neuroscience and will collaborate with UCSF ... work of several researchers at the UCSF Small Molecule ...
Cached Medicine News:Health News:QuestNet and AFC: Raising the Bar of Asian Football 2Health News:QuestNet and AFC: Raising the Bar of Asian Football 3Health News:Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 3Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 4Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 5Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 6Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 7Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 8Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 9Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 10Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 11Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 12Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 13Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 14Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 15Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 16Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 17Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 18Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 19Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 20Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 21Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 22Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 23Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 24Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 25Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 26Health News:Biotel Announces Results for Second Quarter ended December 31, 2009 2Health News:Biotel Announces Results for Second Quarter ended December 31, 2009 3Health News:Centene Corporation to Webcast Medical Management Systems Update 2Health News:Centene Corporation to Webcast Medical Management Systems Update 3Health News:Centene Corporation to Webcast Medical Management Systems Update 4Health News:UCSF enters drug discovery agreement with Genentech 2Health News:UCSF enters drug discovery agreement with Genentech 3
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... system uses prolene as thread-guide reducing time and ... Probe is inserted into the nasolacrimal duct and ... The probe is then withdrawn leaving the polypropylene ... diam silicone tubing into place. Newly coated with ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... conforms to natural anatomy of the ... on disposable inserter/dilator instrument for ease ... The Micro-Large plugs feature the unique ... shape of the eyelid. The slightly ...
Medicine Products: